Selection of Surgical Methods in the Treatment of Upper Tibia Osteosarcoma and Prognostic Analysis

Abstract

Background: We aimed to explore the clinical effects and prognosis of different surgical methods in upper tibia osteosarcoma. Methods: Among 112 patients with proximal upper tibia osteosarcoma, 40 patients were treated with amputation, 20 patients were treated with massive osteoarticular allograft, and the remaining 52 cases were treated with tumor resection and artificial joint replacement. Results: Recurrence was observed in 2 cases (5%) in the amputation group, in 6 cases (30%) in the massive osteoarticular allograft group, and in 6 cases (12%) in the tumor resection and artificial joint replacement group (P = 0.021). The lung metastasis rates were 40% in the amputation group, 40% in the massive osteoarticular allograft group, and 38% in the tumor resection and artificial joint replacement group (P = 0.986). The survival rates at 1, 3, and 5 years were 95%, 75%, and 45%, respectively, in the amputation group, 95%, 75%, and 35%, respectively, in the massive osteoarticular allograft group, and 92.3%, 78.8%, and 53.8%, respectively, in the tumor resection and artificial joint replacement group (P > 0.05). Conclusions: The selection of the optimal surgical method for upper tibia osteosarcoma should be made according to the individual circumstances of the patient. Our study has significance for reducing the incidence of surgical complications and improving the quality of postoperative life.

Limb-salvage surgery offers better five-year survival rate than amputation in patients with limb osteosarcoma treated with neoadjuvant chemotherapy. A systematic review and meta-analysis

“…One hundred and seven articles were excluded based on the inclusion criteria, while 23 articles were excluded, as they studied the same patient population, estimated from the institution, number of patients and name of the authors. At last, 13 articles met the inclusion criteria and were eligible for analysis [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [26] , [27] . Screening and selection details are depicted in Fig.…”

“…We included 12 studies [15] , [16] , [17] , [18] , [19] , [20] , [21] , [22] , [23] , [24] , [25] , [27] analyzing the 5-year overall survival rate in 2826 patients; 1943 patients were treated with LSS and 883 with amputation. The overall pooled analysis demonstrated that the odds of 5-year overall survival was almost 2-fold in patients treated with LSS than those treated with amputation but with substantial heterogeneity (OR: 1.99; 95% CI: 1.35–2.93; I 2 = 74%, p < 0.001) ( Fig.…”

<p>lncRNA LSINCT5 Regulates miR-20a-5p/XIAP to Inhibit the Growth and Metastasis of Osteosarcoma Cells</p>

“…At present, the main clinical treatment of OS is mainly surgery, but in most cases, the tumor of patients diagnosed with OS has transferred to the lungs, which greatly reduces the effectiveness of treatment and affects the prognosis of patients. 3,5 Although the prognosis of some patients can be improved through radiotherapy and chemotherapy, long-term drugs can easily lead to drug resistance and tumor relapse, and lower the survival of patients for the long term. 6 Thus, it is a must to better understand the pathogenesis and molecular mechanism of OS, which will contribute to the clinical treatment and prognosis of OS.…”

<p>Elevated Expression of miR-629 Predicts a Poor Prognosis and Promotes Cell Proliferation, Migration, and Invasion of Osteosarcoma</p>

“…Osteosarcoma (OS) is the most common primary malignant tumor of bone tissue, occurring mainly in adolescents and young adults. 1 Due to the characteristics of early metastasis and poor prognosis of OS, this aggressive malignant tumor has become a major cause of death-threatening adolescents and young adults. Although great progress in the diagnosis and treatment of OS in surgery, radiotherapy, chemotherapy and other aspects, the 5-year overall survival of OS patients has significantly improved to approximately 60-70%.…”